Subcutaneous IFN- injections have been reported to be effective for the treatment of uveitis.[[33]] A principal disadvantage of systemic IFN therapy, flu like symptoms, might be obviated if INF could be delivered in the eye by gene therapy. Although uveitis refers to inflammation of the uvea or vascular layers of eye (the iris, ciliary body, and choroid), the term is commonly used to denote any inflammatory process occurring in the eye. Due to the limited disease course in uveitis models, gene therapy treatments are typically administered before the induction of the ocular inflammatory disease mimicking a prevention strategy rather than the treatment strategies needed for the clinical setting in which patients will present with ongoing ocular inflammation. EYS606, a nonviral gene therapy that turns the ciliary muscle into a biofactory for the sustained intraocular expression of a soluble TNF receptor fusion protein, is the first gene therapy treatment to reach the stage of clinical development. [Extracted from the article]